After a median follow-up of 34 months , PFS was improved in patients who received rituximab/bevacizumab compared with patients who received rituximab alone ( median 20.7 vs. 10.4 months respectively ; HR , 0.40 ( 95 % confidence interval [ CI ] , 0.20-0 .80 ) ; P = .007 ) .